FREEMONT, Calif. (PRWEB) May 23, 2018
Myoscience, Inc. announced today the appointment of Brian Farley as Chairman of the Board of Directors and Edward Kleinhans as the company’s Interim CEO.
Mr. Farley is a veteran medtech industry executive who has built and led multiple successful medical device companies from the early stages through strong commercial growth, IPO, and sales of the businesses. Mr. Farley currently serves as Chairman of the Board of Neuronetics Inc., a commercial stage medtech company focused on the treatment of depression, and is a Director of Neurolutions Inc., a medtech company developing solutions for post-stroke rehabilitation. Recently, Mr. Farley served as Chairman of the Board of Entellus Medical, Inc. and also served as the company’s Chief Executive Officer from 2010 to 2015, leading the company in a successful IPO in early 2015. In February 2018, Stryker Corporation completed an acquisition of Entellus Medical.
Prior to joining Entellus, Mr. Farley was President and CEO of VNUS Medical Technologies, Inc. He joined VNUS in 1995 as the first employee and led the company to become the market leader in the minimally invasive treatment of venous insufficiency. Mr. Farley led VNUS in a successful IPO in 2004 and in June 2009, VNUS was sold to Covidien. Prior to VNUS, Mr. Farley held various management and executive positions in research and development, clinical research and business development for Guidant Corporation, and in the medical division of Eli Lilly and Company. Mr. Farley holds both a B.S. in Engineering and an M.S. in Electrical Engineering with a Biomedical Engineering major from Purdue University.
“I am very pleased with the appointment of Brian Farley as Chairman of the Board of Directors for Myoscience. Brian is a seasoned executive with a tremendous record of success. We are excited to have Brian accept the position at this critical time for the company,” said Jan Pensaert (Valiance Asset Management, Ltd.), a member of the Board of Directors.
“I am honored to assume the role of Chairman for Myoscience and help the Board of Directors and management through the Company’s next phase of business and commercial expansion,” said Mr. Farley. “The Myoscience team has built an extremely strong platform technology that targets peripheral nerve pain. The initial commercial focus in orthopedic pain management related to total knee replacement and osteoarthritis of the knee is in areas with significant clinical need and tremendous market opportunity. The company is at an exciting stage with early market adoption underway and facilitated by strong clinical evidence that shows the company’s iovera° product enables immediate pre- and post-operative pain relief, shortens the patient’s length of stay, and reduces opioid narcotic medication use. We are enthused about the near-term opportunities in these markets and expanding iovera° into other applications.”
Mr. Kleinhans has been serving as the company’s Chief Business Officer since October, 2017. Prior to joining Myoscience, Mr. Kleinhans served as Corporate Strategy and Legal Adviser for Hansen Medical, Inc., advising the company on its sale to Auris Surgical Robotics for $80 million in July 2016. Prior to joining Hansen, Mr. Kleinhans served as Chief Operating Officer for Vaquero Capital and served as Vice President, General Counsel, at Care Innovations, an Intel-GE joint venture company.
The Myoscience board of directors would like to thank former CEO Cary Vance for his leadership, strategic guidance, and many contributions during his tenure as Chief Executive Officer at Myoscience.
For additional information, please visit http://www.iovera.com or email us directly at mediarelations(at)myoscience.com.
Silicon Valley, California-based Myoscience is a privately-held medical device company committed to making its platform technology, the iovera° system, the standard of care for the treatment of peripheral nerves. The iovera° treatment is powered by a patented miniaturization of traditional cryotherapy. The ioveraº system is 510k cleared in the U.S. for the blocking of pain, the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days and general surgical use. For more information, please visit http://www.iovera.com.
© 2018 Myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of Myoscience. MKT-0493 REV A